Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Strategic Expansion into AI-Powered Healthcare Solutions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theralase Technologies Inc. V.TLT.W


Primary Symbol: V.TLT Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Recent & Breaking News (TSXV:TLT)

Theralase (V.TLT) further demonstrates phenomenal cancer immunity response in testing

Gaalen Engen November 12, 2014

Theralase Further Validates Anti-Cancer Memory Response

TheNewsWire November 12, 2014

Theralase Presents Latest Research on Destruction of Cancer and Bacteria at International Conference

TheNewsWire October 16, 2014

Theralase Partners with SAFC in Manufacture of Anti-Cancer Drugs

TheNewsWire October 7, 2014

Theralase Files Voluntary Annual Information Form

TheNewsWire September 24, 2014

Theralase Partners with Montreal's JSS Medical Research to Bring Innovative Bladder Cancer Treatment to Market

TheNewsWire September 11, 2014

Theralase Launches Multi Wavelength Laser for Cancer Destruction

TheNewsWire September 9, 2014

Theralase Releases 2Q2014 Financials

TheNewsWire August 29, 2014

Microcap Report: Theralase Tech. (V.TLT) active on PDC update

Stockhouse Editorial July 17, 2014

Theralase Technologies (V.TLT) furthers anti-cancer tech intellectual property, up 8%

Gaalen Engen July 17, 2014

Theralase Advances Intellectual Property of Anti-Cancer Technology

TheNewsWire July 17, 2014

Theralase Grants Stock Options

TheNewsWire July 16, 2014

Theralase Technologies Treats 1 Million Patients, CEO Clip Video

Newsfile June 30, 2014

Theralase (V.TLT) releases significant peer-reviewed anti-cancer memory response research

Gaalen Engen June 24, 2014

Theralase Releases Peer-Reviewed Research on Anti-Cancer Memory Response and Destruction of Cancerous Cells

TheNewsWire June 24, 2014

Microcap Report: Theralase Tech. (V.TLT), Enablence Tech. (V.ENA) active

Stockhouse Editorial June 18, 2014

Theralase Technologies (V.TLT) teams with University of Toledo in cancer study

Stockhouse Editorial June 18, 2014

Theralase Partners with University of Toledo in Cancer Research

TheNewsWire June 18, 2014

Theralase's Cancer Technology Demonstrates Vaccine-Like Properties

Accesswire June 16, 2014

14 stocks Stockhouse staffers think will have a big June

Stockhouse Editorial June 15, 2014